Clinical trials: Metastasis Colorectal Cancer
Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC)
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
This is a single-arm, multi-center, exploratory study evaluating the efficacy and safety of iparomlimab and tuvonralimab (QL1706) in combination with bevacizumab for the treatment of patients with microsatellite instability-high…
- Conditions
- Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer
- Trial name
- NCT07009145
- Testing
- QL1706, Bevacizumab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Qianfoshan Hospital
Metastatic Colorectal Cancer
A Randomized Phase III Study Comparing Maintenance Treatment With Fluoropyrimidine + Bevacizumab Versus Fluoropyrimidine After Induction Chemotherapy for a Metastatic Colorectal Cancer
The aim of BEVAMAINT is to improve benefic effect of maintenance therapy after a first line of induction chemotherapy for patients with colorectal cancer
- Trial name
- BEVAMAINT (NCT04188145)
- Testing
- Fluoropyrimidine, Bevacizumab
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Cancer
Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003
A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with Penpulimab (AK105) in patients with Chemo-refractory Metastatic Colorectal Cancer (mCRC)
- Trial name
- ALTER-C003 (NCT04970914)
- Testing
- Anlotinib, Penpulimab
- Where
- 8 sites in China
- Volunteers
- 32 people
- Sponsor
- Peking Union Medical College Hospital
Colon Carcinoma, Lymph Node Metastases
Lymph Node Mapping Via Flourescent Dye in Colon Cancer
The aim of the study is to evaluate whether lymph nodes draining the region of the carcinoma are located only inside the lines of standard resection or in some percentages are located outside as well.
- Trial name
- NCT04959604
- Testing
- ICG-marking endoscopically
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Colorectal Cancer
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
RATIONALE: Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways.
- Trial name
- NCT00940316
- Testing
- panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
- Where
- 10 sites in United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Metastatic Colorectal Cancer
Patients' Guidance With Onco-Coaching and CANKADO on Systemic Chemotherapy for Metastatic Colorectal Cancer
This is a prospective, single arm, non-interventional project to evaluate the benefit/influence of individualized patient education and guidance with a web-based e-Health platform called CANKADO on patient reported outcomes (PRO)…
- Trial name
- POSCA (NCT04393116)
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Cankado GmbH
Colorectal Cancer, Neoplasm Metastasis
Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer
The purpose of this study is to investigate whether bevacizumab helps 5-Fluorouracil (5-FU) be delivered to the tumor more efficiently.
- Trial name
- NCT00165568
- Testing
- Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Dynamic Tumor Resistance, Metastatic Colorectal Cancer
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
- Trial name
- NCT07318389
- Testing
- SOC (Standard of care), Bevacizumab, Cetuximab
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
This research study will test the safety of the investigational drug, ZD6474, in combination with 2 other drugs that are standard in the treatment of colon and rectal cancer (cetuximab and irinotecan).
- Trial name
- NCT00436072
- Testing
- ZD6474, Cetuximab, Irinotecan
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
Colon Cancer, Rectal Cancer
Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)
The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients.
- Trial name
- DIAMOND (NCT07306390)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Colorectal Neoplasms, Colorectal Cancer
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
This is an open-label, parallel-group, phase 2 randomized trial which randomizes patients with isolated resectable colorectal cancer peritoneal metastases to receive preoperative systematic therapy followed by CRS+HIPEC and…
- Conditions
- Colorectal Neoplasms, Colorectal Cancer, Colorectal Cancer Metastatic, Peritoneal Metastases
- Trial name
- NCT05353582
- Testing
- Preoperative systematic therapy, CRS+HIPEC, Postoperative chemotherapy
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Sun Yat-sen University
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
Accrue samples for the further development and clinical validation of a blood-based cell-free DNA (cfDNA) quantitative real-time polymerase chain reaction (qPCR) assay as a potential biomarker for early non-response to therapy in…
- Conditions
- Metastatic Non-Small Cell Lung Carcinoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer
- Trial name
- NCT03892096
- Testing
- Blood-based cell-free cfDNA qPCR assay
- Where
- 12 sites in United States, Canada
- Volunteers
- 130 people
- Sponsor
- Cadex Genomics
Colorectal Cancer (CRC)
Savolitinib Plus Cetuximab and FOLFOX Chemotherapy for RAS/BRAF Wild-type Metastatic Colorectal Cancer
The goal of this clinical trial is to learn if adding savolitinib to cetuximab plus FOLFOX chemotherapy works as a first-line treatment for patients with RAS/BRAF wild-type metastatic colorectal cancer, and to evaluate its…
- Trial name
- NCT07683403
- Testing
- Savolitinib plus cetuximab and FOLFOX chemotherapy, Cetuximab and FOLFOX chemotherapy
- Where
- 5 sites in China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Colorectal Neoplasms, Peritoneal Neoplasms
PIPAC for Peritoneal Metastases of Colorectal Cancer
This is multicentre, open-label, single-arm phase II study that investigates the feasibility, safety, tolerability, preliminary efficacy, costs, and pharmacokinetics or repetitive electrostatic pressurised intraperitoneal aerosol…
- Conditions
- Colorectal Neoplasms, Peritoneal Neoplasms, Appendiceal Neoplasms, Peritoneal Carcinomatosis
- Trial name
- CRC-PIPAC (NCT03246321)
- Testing
- repetitive ePIPAC-OX
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Koen Rovers
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult…
- Conditions
- Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT07169734
- Testing
- ALE.P03
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 180 people
- Sponsor
- Alentis Therapeutics AG
Colorectal Cancer Metastatic
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
The aim oh this study is to determine the safety and recommended dose of trifluridine/tipiracil plus capecitabine and bevacizumab combination (part 1, dose escalation phase) and to assess its activity in previously untreated mCRC…
- Trial name
- TriComB (NCT04564898)
- Testing
- Capecitabine, Bevacizumab, Trifluridine/Tipiracil
- Where
- 2 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Colorectal Cancer, Metastatic Colorectal Cancer
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunotherapy and chemotherapy because…
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Refractory Colorectal Carcinoma
- Trial name
- NCT06221423
- Testing
- Fruquintinib Combined With TAS-102
- Where
- China
- Sponsor
- Fudan University
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.